Luo, Wenchen
Sun, Minli
Wan, Jie
Zhang, Zhenyu
Huang, Jian
Zhang, Jinlin
Xiong, Wanxia
Xia, Lirong
Xu, Peiyao
Miao, Changhong
Zhang, Xuesong
Liu, Mingyue
Zhong, Jing
Funding for this research was provided by:
Fujian National Science Foundation (2022J05331)
National Natural Science Foundation of China (82072213, 81971868)
Smart Health-care Project of Zhongshan Hospital (2020ZHZS25)
Post-graduate Medical Education Project of Shanghai Medical College Fudan University (FDYXYBJ-20221003)
Youth Fund of Zhongshan Hospital (2021-011)
Program of Shanghai Academic/Technology Research Leader (20XD1423000)
Clinical Research Project of Zhongshan Hospital (2020ZSLC41)
Excellent Backbone Plan Of Zhongshan Hospital (2021ZSGG16)
Article History
Received: 4 January 2023
Accepted: 14 April 2023
First Online: 26 May 2023
Declarations
:
: The study was approved by the Ethics Committee of Zhongshan Hospital (Number B2021–360) and was registered with the Chinese Clinical Trial Registry prior to patient enrollment (ChiCTR2100048904; Principal investigator: CM; Date of registration: July 19, 2021). The trial was modified on September 23, 2021 to add an additional arm to test RT + flumazenil. Patients were recruited from October 2021 to December 2021 at Zhongshan Hospital Fudan University, Shanghai, China. Written informed consent was obtained from all participants included in the study. This manuscript adheres to the applicable Consolidated Standards of Reporting Trials guidelines. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: The authors have no conflicts of interest related to this work.